Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 24

1.

Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.

Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan A, Simone CB 2nd, Langer C, Katz SI.

Curr Probl Diagn Radiol. 2018 Jan 31. pii: S0363-0188(17)30261-X. doi: 10.1067/j.cpradiol.2018.01.005. [Epub ahead of print]

PMID:
29573843
2.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 Feb 21. pii: S1525-0016(18)30068-6. doi: 10.1016/j.ymthe.2018.02.015. [Epub ahead of print]

PMID:
29550074
3.

Early detection of thymidylate synthase resistance in non-small cell lung cancer with FLT-PET imaging.

Chen X, Yang Y, Katz S.

Oncotarget. 2017 Jul 31;8(47):82705-82713. doi: 10.18632/oncotarget.19751. eCollection 2017 Oct 10.

4.

The value of delayed phase enhanced imaging in malignant pleural mesothelioma.

Patel AM, Berger I, Wileyto EP, Khalid U, Torigian DA, Nachiappan AC, Barbosa EM Jr, Gefter WB, Galperin-Aizenberg M, Gupta NK, Simone CB 2nd, Haas AR, Alley EW, Singhal S, Cengel KA, Katz SI.

J Thorac Dis. 2017 Aug;9(8):2344-2349. doi: 10.21037/jtd.2017.07.86.

5.

Immunotherapy and radiation therapy for malignant pleural mesothelioma.

Alley EW, Katz SI, Cengel KA, Simone CB 2nd.

Transl Lung Cancer Res. 2017 Apr;6(2):212-219. doi: 10.21037/tlcr.2017.04.01. Review.

6.

Pulmonary Tuberculosis: Role of Radiology in Diagnosis and Management.

Nachiappan AC, Rahbar K, Shi X, Guy ES, Mortani Barbosa EJ Jr, Shroff GS, Ocazionez D, Schlesinger AE, Katz SI, Hammer MM.

Radiographics. 2017 Jan-Feb;37(1):52-72. doi: 10.1148/rg.2017160032. Review.

PMID:
28076011
7.

Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group.

Armato SG 3rd, Blyth KG, Keating JJ, Katz S, Tsim S, Coolen J, Gudmundsson E, Opitz I, Nowak AK.

Lung Cancer. 2016 Nov;101:48-58. doi: 10.1016/j.lungcan.2016.09.003. Epub 2016 Sep 5. Review.

8.

Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.

Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI.

Oncotarget. 2017 Apr 11;8(15):24213-24223. doi: 10.18632/oncotarget.12085.

9.

Partial anomalous venous drainage of the left upper lobe during a robot-assisted pulmonary resection.

Gaffey AC, Ball C, Katz S, Singhal S.

J Thorac Dis. 2016 Jul;8(7):E517-9. doi: 10.21037/jtd.2016.05.44.

10.

North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study.

Gill RR, Naidich DP, Mitchell A, Ginsberg M, Erasmus J, Armato SG 3rd, Straus C, Katz S, Patios D, Richards WG, Rusch VW; Malignant Mesothelioma Volumetric CT Study Group.

J Thorac Oncol. 2016 Aug;11(8):1335-1344. doi: 10.1016/j.jtho.2016.04.027. Epub 2016 May 12.

11.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM.

Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.

12.

Extracellular protease imaging for cell mass tracking of xenografted human malignant pleural mesothelioma.

Zhou L, El-Deiry W, Wang W, Ingram ME, Katz SI.

Oncol Rep. 2012 Sep;28(3):883-8. doi: 10.3892/or.2012.1888. Epub 2012 Jun 26.

PMID:
22751990
13.

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.

Sci Transl Med. 2011 Aug 10;3(95):95ra73. doi: 10.1126/scitranslmed.3002842.

14.

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 1;12(3):229-38. Epub 2011 Aug 1.

PMID:
21725212
15.

A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment.

Nowak AK, Francis RJ, Katz SI, Gerbaudo VH.

PET Clin. 2011 Jul;6(3):299-311. doi: 10.1016/j.cpet.2011.04.002.

PMID:
27156725
16.

Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.

Gerbaudo VH, Katz SI, Nowak AK, Francis RJ.

PET Clin. 2011 Jul;6(3):275-97. doi: 10.1016/j.cpet.2011.04.001. Epub 2011 Jun 14.

PMID:
27156724
17.

A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.

Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, Heitjan DF, Litzky L, Friedberg J, Culligan M, June CH, Carroll RG, Albelda SM.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9. doi: 10.1164/rccm.201103-0554CR. Epub 2011 Jun 3.

18.

FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.

Katz SI, Zhou L, Ferrara TA, Wang W, Mayes PA, Smith CD, El-Deiry WS.

Int J Oncol. 2011 Jul;39(1):91-100. doi: 10.3892/ijo.2011.1019. Epub 2011 Apr 29.

PMID:
21537838
19.

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.

Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, Wang X, Heitjan DF, Litzky L, June CH, Vonderheide RH, Carroll RG, Albelda SM.

Mol Ther. 2010 Apr;18(4):852-60. doi: 10.1038/mt.2009.309. Epub 2010 Jan 12.

20.

Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.

Supplemental Content

Loading ...
Support Center